Dr. Peter KrugerUrogynecology & Surgery
Minimally Invasive Surgery

Botulinum Toxin Bladder Injections

Cystoscopic injection of botulinum toxin for refractory overactive bladder.

Overview

Botulinum toxin (Botox) can be injected into the bladder muscle via cystoscopy to treat overactive bladder (OAB) that has not responded to conservative measures and medications. The toxin causes relaxation of the bladder muscle, reducing urgency and allowing the bladder to store more urine.

Normal bladder function

Overactive bladder contracting inappropriately

When Is It Considered?

Botox bladder injections are typically offered when:

  • Lifestyle modifications and bladder training have been insufficient
  • Oral OAB medications have not been effective or have caused intolerable side effects
  • Symptoms significantly affect quality of life

The Procedure

Botulinum toxin injection via cystoscope into bladder wall

  • Performed as an outpatient procedure using a cystoscope (small camera inserted into the bladder through the urethra)
  • Local anesthetic is instilled into the bladder prior to injection
  • Multiple small injections of botulinum toxin are placed into the bladder wall
  • The procedure takes approximately 15-20 minutes

Effectiveness

  • Up to 80% of patients experience significant improvement
  • Effects typically last 6-9 months
  • Repeat injections are needed when symptoms return

Post-Procedure

  • You can usually return to normal activities the same day
  • Improvement may be noticed within 1-2 weeks
  • A follow-up appointment is typically scheduled to assess effectiveness and check for retention
  • The procedure can be repeated as needed, with consistent effectiveness across treatments

Risks and Success Rates

Botulinum toxin bladder injections achieve significant improvement in approximately 60% of patients with overactive bladder symptoms. Symptom relief typically begins within the first 2 weeks, with effects lasting 6-9 months on average before repeat treatment is needed. Potential risks include:

  • Urinary tract infection — occurs in approximately 1 in 12 patients (about 8%)
  • Temporary self-catheterization — approximately 1% of patients may temporarily need to self-catheterize due to incomplete bladder emptying
  • Blood in the urine — may occur briefly after the procedure
  • Allergic reactions — rare, including anaphylaxis
  • Generalized weakness — very rare

Illustrations courtesy of the International Urogynecological Association (IUGA) Patient Information Leaflets.